GSK has made a good start to the year, with a visible recovery in all of the business segments. Although, strong Q1 performance was partly also driven by higher Xevudy sales and some ‘one-offs’. Having said that, profitability improvement sustained despite a higher contribution from low-margin Xevudy. Moreover, the on-track separation of the consumer business was the icing on the cake. Overall our positive stance on the UK giant is maintained.
27 Apr 2022
Material Q1 beat, but guidance remains unchanged
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Material Q1 beat, but guidance remains unchanged
GSK plc (GSK:LON) | 1,638 -245.8 (-0.9%) | Mkt Cap: 67,914m
- Published:
27 Apr 2022 -
Author:
Amandeep Goyal -
Pages:
5
GSK has made a good start to the year, with a visible recovery in all of the business segments. Although, strong Q1 performance was partly also driven by higher Xevudy sales and some ‘one-offs’. Having said that, profitability improvement sustained despite a higher contribution from low-margin Xevudy. Moreover, the on-track separation of the consumer business was the icing on the cake. Overall our positive stance on the UK giant is maintained.